Market Overview - The Chinese medical device market is expected to grow to 1.66 trillion yuan by 2030, with significant growth potential in the medical consumables sector[2] - The global medical device industry reached a total scale of $47.936 billion in 2023, projected to grow to $63.796 billion by 2028[2][7] - By 2025, China's medical device market is anticipated to reach 1.2442 trillion yuan, with a compound annual growth rate (CAGR) of 14.76% from 2017 to 2024[9] Medical Consumables Insights - In 2024, the medical consumables market in China is expected to account for 63.18% of the total medical device market, with a market size of approximately 595 billion yuan[14] - The high-value medical consumables market in China grew from 60.2 billion yuan in 2015 to 250.4 billion yuan in 2024, reflecting a CAGR of 17.2%[15] - The vascular intervention consumables segment is the largest, projected to reach about 91.8 billion yuan in 2024, representing 36.7% of the high-value consumables market[15] Market Performance - The median stock price change for the North Exchange's consumer service sector was -3.78% from March 23 to March 27, 2026, with 7% of companies experiencing an increase[37] - The total market capitalization of the North Exchange consumer service sector decreased from 100.036 billion yuan to 95.322 billion yuan during the same period[41] - The median price-to-earnings (P/E) ratio for the North Exchange consumer service sector fell from 37.5X to 36.5X[40] Company Announcements - Yisheng Mushrooms reported a revenue of 739.29 million yuan for 2025, a year-on-year increase of 19.91%, but a net profit decline of 23.05%[54] - The company plans to distribute a cash dividend of 5.00 yuan per 10 shares, totaling approximately 51.52 million yuan[54]

股东拟减持股份的预披露公告（再次披露） 本公司及董事会全体成员及相关股东保证公告内容不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 | 股东名称 | 股东身份 | 持股数量 | 持股比例（%） | 当前持股股份来源 | | --- | --- | --- | --- | --- | | | | （股） | | | | 王敏 | 董事长 | 25,417,114 | 25.8145% | 北交所上市前取得 | | 王芳 | 总经理 | 19,064,636 | 19.3627% | 北交所上市前取得 | | 惠州市锦同 声投资合伙 | 实际控制人 之一致行动 | 3,149,992 | 3.1992% | 北交所上市前取得 | | 企业（有限 | 人 | | | | | 合伙） | | | | | 证券代码：920925 证券简称：锦好医疗 公告编号：2026-017 惠州市锦好医疗科技股份有限公司 一、 减持主体的基本情况 二、 本次减持计划的主要内容 | | 计划减持 | 计划减 持数量 | | | 减持 | | | | --- | --- | --- | --- ...

证券代码：920925 证券简称：锦好医疗 公告编号：2026-016 惠州市锦好医疗科技股份有限公司 （一）信息披露义务人基本情况 | 1、基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | 惠州市锦同盛投资合伙企业（有限合伙） | | | | 权益变动时间 | | 2026 年 3 月 12 日 | | | 证券简称 | 锦好医疗 | 股票代码 | 920925 | | 变动类型 | 增加□ 减少√ | 是否为公司控股 股东、实际控制人 及其一致行动人 | 是√ 否□ | | 2、本次权益变动情况 | | | | | --- | --- | --- | --- | | 股东名称 | 变动方式 | 减持股数（股） | 减持比例 | | 惠州市锦同盛投资 | | | | | 合伙企业（有限合 | 集中竞价 | 73,200 | 0.0743% | | 伙） | | | | （二）本次权益变动前后，信息披露义务人及其一致行动人拥有上市公司 权益的股份情况 | 股东名称 | 股份性质 | 本次权益变动前持有股份 | | 本次权益变动后持有股份 | | | --- ...

| | 计划减持 | 计划减 持数量 | | | 减持 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | | | 减持 | 减持 | | 拟减持股 | 拟减持 | | 称 | 数量 | 占总股 | 方式 | 期间 | 价格 | 份来源 | 原因 | | | （股） | 本比例 | | | 区间 | | | | | | （%） | | | | | | | 王敏 | 不高于 | 0.5992 | 集中竞 | 公司披露本 减持计划公 | 市场 | 北交所上 | 自身资 | | | 股 590,000 | % | 价或大 | 告之日起 | 价格 | 市前取得 | 金需要 | | | | | 宗交易 | 30 个交易 | | | | | | | | | 日后 个月 3 | | | | 证券代码：920925 证券简称：锦好医疗 公告编号：2026-015 惠州市锦好医疗科技股份有限公司 股东拟减持股份的预披露公告 本公司及董事会全体成员及相关股东保证公告内容不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任 ...

Performance Overview - The company reported a revenue of 308 million yuan for 2025, representing a year-on-year growth of 65.26%. The net profit reached 15.1578 million yuan, showing a significant increase of 153.62% [1] Company Status - On January 9, 2026, the company announced an employee stock ownership plan draft involving 48 core employees, with a lock-up period of 14 months. The performance assessment targets include a sales volume or net profit growth rate of no less than 12% for 2026. The implementation and its impact on team stability will be worth monitoring [2] Funding Dynamics - The fourth extraordinary general meeting of shareholders approved the bank credit limit for 2026, with the resolution announced on January 6, 2026. Attention should be paid to whether the actual allocation of funds supports business expansion or technological upgrades [3] Business Progress - Following the acquisition of Intricon's hearing health business in 2024, the sales revenue from hearing aid chips reached approximately 20 million yuan in 2025, showing significant year-on-year growth. The demand for OTC hearing aids in the U.S. continues to rise amid global aging trends, and future focus may be on technology integration and omnichannel operations [4]

证券代码：920925 证券简称：锦好医疗 公告编号：2026-014 惠州市锦好医疗科技股份有限公司 关于使用部分闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）购买理财产品的审议情况 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第三届董事会第十七次会议审议通过《关于使用部分闲置自有资金购买银 行理财产品的议案》。为提高公司资金使用效率，在确保资金安全、不影响公司 正常经营的前提下，公司合理利用部分暂时闲置自有资金购买银行理财产品。使 用额度不超过人民币 10,000 万元的自有闲置资金购买安全性高、流动性好、风 险较低的理财产品，在此额度内可以循环滚动使用。具体内容详见公司 2025 年 10 月 29 日在北京证券交易所（www.bse.cn）披露的《关于使用部分闲置自有资 金购买银行理财产品的公告》（公告编号：2025-122）。 （二）购买理财产品的披露标准 根据《北京证券交易所股票 ...

Group 1 - The core point of the article is that Jinhao Medical (920925) reported a significant increase in net profit for 2025, with a growth rate of 153.62% compared to the previous year [1][2] - As of February 9, 2026, Jinhao Medical's stock closed at 22.73 yuan, reflecting a 0.71% increase with a trading volume of 12,600 shares and a total transaction amount of 28.57 million yuan [1] - On February 9, the main capital inflow was 2.7391 million yuan, accounting for 9.59% of the total transaction amount, while retail investors saw a net inflow of 346,400 yuan, representing 1.21% of the total [1][2] Group 2 - The company is set to release its annual report for 2025, which is anticipated to confirm the reported net profit of 0.0152 billion yuan [1][2]

Core Viewpoint - The company reported significant growth in both revenue and profit for the year 2025 compared to the previous year, indicating strong financial performance and operational efficiency [1]. Financial Performance - The company's operating revenue for 2025 reached 308 million yuan, up from 186 million yuan in the previous year, representing a year-on-year increase of 65.26% [1]. - The total profit amounted to 17.56 million yuan, compared to 4.75 million yuan in the prior year, reflecting a substantial year-on-year increase of 270.03% [1]. - The net profit attributable to shareholders was 15.16 million yuan, an increase from 5.98 million yuan in the previous year, marking a year-on-year growth of 153.62% [1].

一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 307,520,582.32 | 186,077,884.38 | 65.26% | | 利润总额 | 17,563,298.21 | 4,746,488.00 | 270.03% | | 归属于上市公司股 东的净利润 | 15,157,797.44 | 5,976,494.02 | 153.62% | | 归属于上市公司股 东的扣除非经常性 | 11,615,685.64 | 3,614,556.51 | 221.36% | | 损益的净利润 | | | | | 基本每股收益 | 0.15 | 0.06 | 150.00% | | 加权平均净资产收 益率%（扣非前） | 4.15% | 1.65% | - | | 加权平均净资产收 益率%（扣非后） | 3.18% | 1.00% | - | 证券代码：920925 证券简称：锦好医疗 公告编号：2026-013 惠州市锦好医疗科技股份有限公司 2025 年年度业绩快报公告 本公司及 ...

Group 1 - The core point of the article is that JinHao Medical has announced a restricted stock incentive plan aimed at motivating key personnel, with specific performance targets set for revenue and net profit [1] Group 2 - As of February 4, 2026, JinHao Medical's stock closed at 22.7 yuan, with a market capitalization of 2.235 billion yuan [1] - The stock opened at 22.75 yuan, reached a high of 22.9 yuan, and a low of 22.62 yuan, with a trading volume of 25.5143 million yuan and a turnover rate of 2.03% [1] - The company plans to grant 200,000 shares of restricted stock to three incentive targets at a price of 8.77 yuan per share, with a lock-up period of 12 to 24 months [1] - The performance targets for the company include achieving a minimum revenue of 300 million yuan in 2026 or a cumulative net profit of 55 million yuan over three years, and a minimum revenue of 350 million yuan in 2027 or a cumulative net profit of 90 million yuan over three years [1]